FTC Enforcers Signal Fresh Approach to Pharma Mergers

Speaking at a recent forum on pharmaceutical deals and antitrust, an adviser to acting FTC Commissioner Slaughter said that it’s time to refresh the FTC’s approach to pharma mergers.

READ NOW: Enforcers Shouldn’t Be “Bound by Past” on Theories of Merger Harm, U.S. FTC Official Says in Pharma Discussion

Related Content

• AstraZeneca-Alexion U.S. Clearance Shows Large Pharma Deals Can Still Avoid Deep Probes
  Review strategies for avoiding long investigations in large pharma mergers.
• Pay-for-Delay Deals and Antitrust Concerns
  Read up on another common pharma antitrust issue.

Practical Guidance Updates
Featuring the latest updates in Practical Guidance.

• Federal Merger Enforcement Tracker
• Market Trends 2020: Merger Remedies
• Market Trends 2020: FTC Commissioner Statements in Merger Enforcement Actions
• Document alerts allow you to stay current on legal developments that affect your practice. Find out how to set up your document alerts.

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+